Filtered By:
Specialty: Cancer & Oncology

This page shows you your search results in order of relevance. This is page number 12.

Order by Relevance | Date

Total 1099 results found since Jan 2013.

Primary stroke prevention in Nigerian children with sickle cell disease (SPIN): Challenges of conducting a feasibility trial
ConclusionA hydroxyurea trial (NCT01801423) for children with SCD is feasible in sub‐Saharan Africa; however, extensive training and resources are needed to build a global patient oriented multi‐disciplinary research team with a common purpose. Pediatr Blood Cancer. © 2014 Wiley Periodicals, Inc.
Source: Pediatric Blood and Cancer - November 14, 2014 Category: Cancer & Oncology Authors: Najibah A. Galadanci, Shehu U. Abdullahi, Musa A. Tabari, Shehi Abubakar, Raymond Belonwu, Auwal Salihu, Kathleen Neville, Fenella Kirkham, Baba Inusa, Yu Shyr, Sharon Phillips, Adetola A. Kassim, Lori C. Jordan, Muktar H. Aliyu, Brittany V. Covert, Micha Tags: Research Article Source Type: research

Study Finds Link Between Cancer Diagnosis, Stroke Risk
Title: Study Finds Link Between Cancer Diagnosis, Stroke RiskCategory: Health NewsCreated: 1/7/2015 12:00:00 AMLast Editorial Review: 1/8/2015 12:00:00 AM
Source: MedicineNet Cancer General - January 8, 2015 Category: Cancer & Oncology Source Type: news

Childhood Cancer Survivors Who’ve Had One Stroke at Risk of Second
Rate is double that of people without cancer who've lived through one stroke, study finds
Source: The Doctors Lounge - Oncology - August 26, 2015 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Cardiology, Neurology, Oncology, Pediatrics, News, Source Type: news

Childhood Cancer Survivors Who've Had One Stroke at Risk of Second
Rate is double that of people without cancer who've lived through one stroke, study finds
Source: Cancercompass News: Other Cancer - August 27, 2015 Category: Cancer & Oncology Source Type: news

Associations between hematopoietic growth factors and risks of venous thromboembolism, stroke, ischemic heart disease and myelodysplastic syndrome: findings from a large population-based cohort of women with breast cancer
Conclusions Receipts of CSFs and ESAs were significantly associated with an increased risk of VTE in women with breast cancer. Use of ESAs was significantly associated with substantially increased risks of MDS. These findings support those of previous studies.
Source: Cancer Causes and Control - April 7, 2016 Category: Cancer & Oncology Source Type: research

Breast Cancer Meds Won't Raise Chances of Heart Attack, Stroke, Study Suggests
Title: Breast Cancer Meds Won't Raise Chances of Heart Attack, Stroke, Study SuggestsCategory: Health NewsCreated: 4/21/2016 12:00:00 AMLast Editorial Review: 4/22/2016 12:00:00 AM
Source: MedicineNet Cancer General - April 22, 2016 Category: Cancer & Oncology Source Type: news

Stem cell brain injections let people walk again after stroke
People once confined to wheelchairs because of stroke showed improvements in movement and speech with the help of stem cells injected into the brain
Source: New Scientist - Cancer - June 2, 2016 Category: Cancer & Oncology Source Type: research

A Case Report of Ischemic Stroke in a Patient with Metastatic Gastric Cancer Secondary to Treatment with the Vascular Endothelial Growth Factor Receptor-2 Inhibitor Ramucirumab
Ramucirumab is an antiangiogenesis agent targeting the vascular endothelial growth factor receptor-2 (VEGFR-2), approved to treat advanced gastric and colon cancer. In clinical trials, it was shown to cause a small increase in arterial thromboembolism compared to placebo, including cerebral and myocardial ischemia, which was not statistically significant. Detailed case reports are lacking and we here present one of the first case reports of stroke secondary to ramucirumab-induced in situ thrombosis.Case Rep Oncol 2016;9:317–320
Source: Case Reports in Oncology - June 10, 2016 Category: Cancer & Oncology Source Type: research

Therapeutic effects of umbilical cord blood plasma in a rat model of acute ischemic stroke.
This study provides valuable insights into the development of a safe, effective, and cell-free strategy for the treatment of ischemic brain damage and a much-needed alternative for patients who are ineligible for thrombolytic therapy. PMID: 27816964 [PubMed - as supplied by publisher]
Source: Oncotarget - November 8, 2016 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Walking faster after stroke, managing chemobrain after cancer
(Allina Health) New gate guidelines developed by Courage Kenny Rehabilitation Institute doubled stroke patients' walking speeds. And, occupational therapy helped breast cancer patients manage chemobrain.
Source: EurekAlert! - Cancer - November 29, 2016 Category: Cancer & Oncology Source Type: news

Kidney disease patients have higher out-of-pocket costs than stroke and cancer patients
(Loyola University Health System) Patients who have chronic kidney disease but are not on dialysis have higher out-of-pocket healthcare expenses than even stroke and cancer patients, according to a Loyola University Chicago study published in BMC Nephrology.
Source: EurekAlert! - Cancer - January 17, 2017 Category: Cancer & Oncology Source Type: news

Dimethyl fumarate for ischemic stroke.
Authors: Kunze R PMID: 28209921 [PubMed - as supplied by publisher]
Source: Oncotarget - February 18, 2017 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

microRNA may reduce stroke risk
(Technical University of Munich (TUM)) The molecule microRNA-210 stabilises deposits in the carotid artery and can prevent them from tearing. Thus, it may prevent dangerous blood clots from forming. This is what scientists headed by Prof. Lars M ä gdefessel, Professor of Vascular Biology at the Technical University of Munich (TUM) and head of a junior scientist group in the German Centre for Cardiovascular Research (DZHK) have discovered. Their results open up new treatment approaches to reduce stroke risk in patients with carotid arteries at risk of rupturing.
Source: EurekAlert! - Cancer - April 13, 2017 Category: Cancer & Oncology Source Type: news

Ischemic stroke and intracranial hemorrhage in patients with recurrent glioblastoma multiforme, treated with bevacizumab
AbstractBevacizumab (BVZ), a monoclonal antibody directed against vascular endothelial growth factor (VEGF), has been suspected to increase the incidence of ischemic stroke (IS) and intracranial hemorrhage (ICH) in GBM patients. Intracranial vascular events, such as IS and ICH, were retrospectively analyzed in 364 MRI scans of 82 patients with recurrent GBM (1st/2nd/3rd relapse). Out of these 82 patients, 40 were treated with BVZ (178 scans) in addition to basic treatment, whereas 42 patients matching for age and gender received basic treatment (186 scans). Distribution of typical vascular risk factors between both groups ...
Source: Journal of Neuro-Oncology - May 29, 2017 Category: Cancer & Oncology Source Type: research